Caffeine

The world's most-used cognitive + ergogenic drug, A-tier across cognition, endurance, strength, and combat-sport reaction time at 3-6 mg/kg. Dylan's zero-caffeine baseline is the single most untapped lever in his V4 stack — first 100mg will hit harder than for any habituated user. Pair 1:2 with L-theanine (200mg theanine per 100mg caffeine), keep dosing 2-4×/week to preserve the responder window, and hard-cutoff 8+ hours before target bedtime — the 2024 SLEEP RCT shows 100mg dosed 12h pre-bed still alters architecture, and subjects can't subjectively detect it.

Caffeine is a non-selective antagonist at the four adenosine receptor subtypes, with the brain-relevant action concentrated at A1 and A2A. Unlike the A2A-selective compound KW-6356 (also in this wiki), caffeine blocks both — which is why it has both an "alerting" face and a "ramping" face.

Primary action — A1 antagonism (the "alerting" face):

• A1 receptors are inhibitory, expressed broadly on glutamatergic, cholinergic, noradrenergic, and dopaminergic terminals across cortex and basal forebrain. Their normal job is to dampen neurotransmitter release as adenosine (the catabolite of ATP) accumulates over the waking day — this is the molecular basis of "homeostatic sleep pressure."
• Block A1 → release of glutamate, ACh, NE, DA from these terminals comes back online. Result: subjective alertness, attention, reaction time, working memory, lifted fatigue.
• A1 antagonism is what caffeine does at low doses (50-150mg) and is the dominant feature of its alerting profile.

Secondary action — A2A antagonism (the "motivational/ergogenic" face):

• A2A receptors are concentrated in the striatum (caudate/putamen/nucleus accumbens), where they form heteromers with the dopamine D2 receptor. When adenosine binds A2A, it allosterically dampens D2 signaling — effectively a brake on striatal dopamine tone.
• Block A2A → striatal D2 signaling is disinhibited → indirectly elevated dopaminergic tone in motor and motivational circuits. This is why caffeine improves motor activation, perceived effort, and motivation to engage — the ergogenic mechanism in endurance studies and the "let's go" feel.
• A2A antagonism is also why caffeine is being investigated for Parkinson's (KW-6356 selectivity is what makes it cleaner — see kw-6356.md).

Tertiary actions (less relevant at typical doses):

• Phosphodiesterase inhibition (PDE4, PDE5) — only at supraphysiologic doses (>500-1000mg). Negligible at 100-200mg.
• Ca2+ release from ryanodine receptors in skeletal muscle — only at very high concentrations; not the source of the ergogenic effect at 3-6 mg/kg.
• GABA-A inverse agonism — extremely weak; clinically irrelevant.
• Indirect catecholamine release via sympathetic activation — contributes to peripheral effects (HR/BP rise, mild lipolysis).

Why A1+A2A both matter for the cognitive stack: A1 alone gives you alertness without the motivational push; A2A alone gives you motor-activation without the cortical sharpening (this is why caffeine feels "fuller" than KW-6356-style A2A-selective compounds, but also why it has more peripheral side-effect surface).

Tolerance mechanism: Chronic caffeine exposure produces adenosine A1 receptor upregulation in cortex/hippocampus + A2A upregulation in striatum within ~7-14 days of daily dosing. The brain compensates for the constant blockade by manufacturing more receptors. When caffeine is present, you still get the antagonist effect — but residual (waking) adenosine has more receptors to bind, so baseline (off-caffeine) feels worse than pre-tolerance baseline. The net effect is that the delta between on-caffeine and off-caffeine shrinks, even though the absolute on-caffeine state is similar. Recent literature debates whether A2A or A1 upregulation dominates the tolerance phenotype (Karcz-Kubicha 2003; ahajournals.org platelet data 2000) — likely both, with A1 driving the alerting tolerance and A2A driving the motor-activation tolerance.